Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Más filtros













Base de datos
Intervalo de año de publicación
1.
Eur J Pharm Biopharm ; 146: 1-9, 2020 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-31726218

RESUMEN

Recently there has been an increased interest to develop specialised dosage forms that are better suited to specific patient populations, such as paediatrics and geriatrics. In these patient populations the acceptability of the oral dosage form can be paramount to the products success. However, many Active Pharmaceutical Ingredients (APIs) are known to cause an aversive taste response. One way to increase the acceptability and to enhance the palatability of the formulation is to design coated taste-masked particulate-based dosage forms. The masking of poorly tasting drugs with physical barriers such as polymer coatings can be utilised to prevent the release of drug within the oral cavity, thus preventing a taste response. However, currently, there are few assessment tools and models available to test the efficiency of these particulate-based taste-masked formulations. The rat brief access taste aversion model has been shown to be useful in assessment of taste for liquid dosage forms. However, the applicability of the rat model for particulate-based taste masked formulations is yet to be assessed. It is not understood whether dissolution, solubility and thus exposure of the drug to taste receptors would be the same in rat and human. Therefore, rat saliva must be compared to human saliva to determine the likelihood that drug release would be similar within the oral cavity for both species. In this study rat saliva was characterised for parameters known to be important for drug dissolution, such as pH, buffer capacity, surface tension, and viscosity. Subsequently dissolution of model bitter tasting compounds, sildenafil citrate and efavirenz, in rat saliva was compared to dissolution in human saliva. For all parameters characterised and for the dissolution of both drugs in rat saliva, a substantial difference was observed when compared to human saliva. This discrepancy in saliva parameters and dissolution of model drugs suggests that preclinical taste evaluation of particulate-based taste-masked formulations suggests rat is not a good model for predicting taste of solid dosage forms or undissolved drug where dissolution is required. Alternative preclinical in vivo models in other species, or improved biorelevant in vitro models should be considered instead.


Asunto(s)
Composición de Medicamentos/métodos , Evaluación Preclínica de Medicamentos/normas , Excipientes/química , Ratas/fisiología , Gusto/efectos de los fármacos , Administración Oral , Animales , Agentes Aversivos/administración & dosificación , Química Farmacéutica , Niño , Liberación de Fármacos , Aromatizantes/administración & dosificación , Humanos , Modelos Animales , Mucosa Bucal/metabolismo , Mucosa Bucal/fisiología , Saliva/química , Saliva/fisiología , Especificidad de la Especie , Gusto/fisiología
2.
J Lipid Res ; 53(1): 51-65, 2012 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-22021650

RESUMEN

In an attempt to understand the applicability of various animal models to dyslipidemia in humans and to identify improved preclinical models for target discovery and validation for dyslipidemia, we measured comprehensive plasma lipid profiles in 24 models. These included five mouse strains, six other nonprimate species, and four nonhuman primate (NHP) species, and both healthy animals and animals with metabolic disorders. Dyslipidemic humans were assessed by the same measures. Plasma lipoprotein profiles, eight major plasma lipid fractions, and FA compositions within these lipid fractions were compared both qualitatively and quantitatively across the species. Given the importance of statins in decreasing plasma low-density lipoprotein cholesterol for treatment of dyslipidemia in humans, the responses of these measures to simvastatin treatment were also assessed for each species and compared with dyslipidemic humans. NHPs, followed by dog, were the models that demonstrated closest overall match to dyslipidemic humans. For the subset of the dyslipidemic population with high plasma triglyceride levels, the data also pointed to hamster and db/db mouse as representative models for practical use in target validation. Most traditional models, including rabbit, Zucker diabetic fatty rat, and the majority of mouse models, did not demonstrate overall similarity to dyslipidemic humans in this study.


Asunto(s)
Modelos Animales de Enfermedad , Dislipidemias/sangre , Lípidos/sangre , Animales , Cricetinae , Perros , Dislipidemias/tratamiento farmacológico , Ácidos Grasos/sangre , Humanos , Ratones , Primates , Simvastatina/uso terapéutico , Triglicéridos/sangre
3.
J Pharmacol Exp Ther ; 338(1): 220-7, 2011 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-21459965

RESUMEN

Both the physiological role of muscarinic receptors for bladder function and the therapeutic efficacy of antimuscarinic agents for overactive bladder syndrome are well documented. We investigated the effect of antimuscarinic agents with different subtype selectivity on urodynamic parameters in nonhuman primates and rodents and compared plasma levels of these agents between species. Anesthetized rhesus monkeys were transurethrally catheterized, and the bladder was infused with saline. Urodynamic parameters were measured before and after intravenous drug administration. Tolterodine (nonselective) and oxybutynin (moderately M(3)-selective) increased bladder capacity at lower doses than those required to decrease micturition pressure. However, higher doses of darifenacin (M(3)-selective) were needed to increase the bladder capacity than those needed to decrease the micturition pressure. In rats, tolterodine had no effect on the bladder capacity but decreased the micturition pressure at all of the doses administered. Oxybutynin also decreased micturition pressure and increased bladder capacity at the highest dose. Plasma levels of these drugs overlap in both species. These results suggest that, in addition to the M(3) receptor, other muscarinic receptor subtypes contribute to regulate bladder storage function in nonhuman primates, since less subtype-selective tolterodine and oxybutynin showed higher specificity to the bladder capacity effect than the effect on micturition pressure compared with M(3)-selective darifenacin. In addition, the role of muscarinic receptors in bladder storage function varies between primates and rodents. Compared with rodents, muscarinic receptors may play a more active role during the storage phase to regulate the functional bladder capacity in primates.


Asunto(s)
Antagonistas Muscarínicos/farmacología , Vejiga Urinaria/efectos de los fármacos , Vejiga Urinaria/fisiología , Animales , Compuestos de Bencidrilo/farmacología , Cresoles/farmacología , Femenino , Macaca mulatta , Ácidos Mandélicos/farmacología , Fenilpropanolamina/farmacología , Ratas , Ratas Sprague-Dawley , Especificidad de la Especie , Tartrato de Tolterodina
4.
Lab Anim (NY) ; 38(8): 271-4, 2009 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-19626020

RESUMEN

Urethral catheterization of the female dog is known to be a challenging procedure. The authors describe a catheterization technique in which they use a rigid endoscope to visualize the canine urogenital vestibule during the procedure. The technique is particularly helpful as a training tool for students who are not yet experienced with the canine anatomy. The endoscope is attached to a video camera and monitor, allowing others to observe and learn the procedure.


Asunto(s)
Técnicos de Animales/educación , Endoscopios , Cateterismo Urinario/veterinaria , Animales , Perros , Femenino , Cateterismo Urinario/instrumentación , Cateterismo Urinario/métodos , Grabación de Cinta de Video/instrumentación , Grabación de Cinta de Video/métodos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA